ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc (VNDA)

4.11
0.22
(5.66%)
At close: March 28 04:00PM
4.15
0.26
( 6.68% )
After Hours: 04:33PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
4.15
Bid
4.11
Ask
4.19
Volume
1,370,960
3.91 Day's Range 4.19
3.295 52 Week Range 7.00
Market Cap
Previous Close
3.89
Open
3.92
Last Trade Time
17:02:17
Financial Volume
$ 5,586,162
VWAP
4.0746
Average Volume (3m)
952,476
Shares Outstanding
57,537,499
Dividend Yield
-
PE Ratio
94.27
Earnings Per Share (EPS)
0.04
Revenue
192.64M
Net Profit
2.51M

About Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder... Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include Tradipitant (VLY-686), VTR-297, and VQW-765. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Vanda Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VNDA. The last closing price for Vanda Pharmaceuticals was $3.89. Over the last year, Vanda Pharmaceuticals shares have traded in a share price range of $ 3.295 to $ 7.00.

Vanda Pharmaceuticals currently has 57,537,499 shares outstanding. The market capitalization of Vanda Pharmaceuticals is $236.48 million. Vanda Pharmaceuticals has a price to earnings ratio (PE ratio) of 94.27.

VNDA Latest News

Form 8-K - Current report

false 0001347178 0001347178 2024-03-06 2024-03-06     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZยฎ in the Treatment of Insomnia

Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZยฎ in the Treatment of Insomnia PR Newswire WASHINGTON, March 6, 2024 WASHINGTON, March 6, 2024 /PRNewswire/ -- Vanda...

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">144: Remarks and SignatureRemarksDate of Notice03/04/2024ATTENTION: The person for whose account the securities to which this notice relates are...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.37.792207792213.854.193.796789873.88636693CS
4-0.41-8.991228070184.564.7153.718685393.98282687CS
12-0.18-4.157043879914.334.763.469524763.99779647CS
26-0.47-10.17316017324.624.763.2959307414.01468888CS
52-2.67-39.14956011736.8273.2958962674.74803734CS
156-11.12-72.822527832415.2721.86273.2956273098.85124016CS
260-14.24-77.433387710718.3921.86273.29561702210.62059291CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
QLIQilian International Holding Group Ltd
$ 1.10
(59.44%)
2.31M
SBFMSunshine Biopharma Inc
$ 0.085
(40.50%)
17.98M
XLOXilio Therapeutics Inc
$ 1.22
(12.96%)
730.26k
CGTXCognition Therapeutics Inc
$ 2.05
(12.64%)
2.3k
NUWENewellis Inc
$ 0.4002
(12.57%)
33.53k
XTKGX3 Holdings Company Ltd
$ 0.6599
(-33.35%)
946.79k
NVVENuvve Holding Corporation
$ 0.88
(-20.00%)
52.69k
APLMApollomics Inc
$ 0.641
(-14.53%)
25.47k
WATTEnergous Corporation
$ 1.78
(-12.32%)
7.81k
APLTApplied Therapeutics Inc
$ 6.05
(-11.03%)
147k
SBFMSunshine Biopharma Inc
$ 0.085
(40.50%)
17.98M
CRKNCrown Electrokinetics Corporation
$ 0.061
(1.84%)
4.91M
AAPLApple Inc
$ 171.22
(-0.15%)
3.29M
MSFTMicrosoft Corporation
$ 419.97
(-0.18%)
2.52M
INTCIntel Corporation
$ 44.12
(-0.11%)
2.34M

VNDA Discussion

View Posts
tknuncle tknuncle 2 months ago
I have been acquiring since $3.90. I wish that I would have waited longer lol but, like what I see with VNDA. Was going to grab the last of my starter position soon. GLTA
๐Ÿ‘๏ธ0
weedtrader420 weedtrader420 2 months ago
FDA Approve
๐Ÿ‘๏ธ0
Triple nickle Triple nickle 4 months ago
Fda accepts new drug application for tradipitant in the after hours today
👍️ 1
jgrabar jgrabar 2 years ago
$VNDA -On May 19, 2022, Vanda Pharmaceuticals agreed to settle a securities fraud class action complaint (the โ€œComplaintโ€) for $11.5 Million. https://grabarlaw.com/the-latest/vanda-pharmaceuticals-investigation/
๐Ÿ‘๏ธ0
RNsidersbuying RNsidersbuying 3 years ago
VNDA 12.34 - FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome

https://ih.advfn.com/stock-market/NASDAQ/vanda-pharmaceuticals-VNDA/stock-news/83807075/fda-approves-hetlioz-tasimelteon-for-the-treatmen
๐Ÿ‘๏ธ0
XenaLives XenaLives 4 years ago
Everything would be a lot better if the govt. would just let doctors treat COVID like another flu bug. The drama is getting old.
๐Ÿ‘๏ธ0
Peepson Peepson 4 years ago
Yo, this thing is going to trade sideways for a while. They have a drug that could help with covid but so does every other pharma company. Its a safe hold imo but nothing will happen fast i don't think
๐Ÿ‘๏ธ0
XenaLives XenaLives 4 years ago
What's up? Doesn't seem to be much interest. I was looking at the chart but haven't found much on the company yet.

๐Ÿ‘๏ธ0
otcmoneydoubler otcmoneydoubler 4 years ago
LOL. VNDA GOT NEWS TODAY. SO WHAT DD HAVE YOU GOT TO SHARE?
๐Ÿ‘๏ธ0
Peepson Peepson 4 years ago
Yo, does anyone still follow this board. I might have some interesting dd to share.
๐Ÿ‘๏ธ0
bezen bezen 7 years ago
https://finance.yahoo.com/news/jefferies-5-top-biotech-stocks-133534894.html
๐Ÿ‘๏ธ0
Coz Mabluda Coz Mabluda 7 years ago
Brett Jensen. SA article re VNDA. Expects positive analyst's review.

Vanda Pharmaceuticals (NASDAQ:VNDA) posted solid third quarter results on Thursday. Instead of losing a dime a share as expected, the company posted a profit of 11 cents a share. Revenue was also up more than 35% from the same period a year ago. The company now looks like it could be profitable in FY2017. I expect some positive analyst commentary on this name by analysts over the next week. Vanda has a solid pipeline and over $140 million in cash and marketable securities on the balance sheet. One has to like the company's growth trajectory and the concern seems undervalued with just a $600 million market capitalization.



๐Ÿ‘๏ธ0
stocktrademan stocktrademan 7 years ago
fast and steady profit scan VNDA bullish 16.64



normal chart


log chart

๐Ÿ‘๏ธ0
ClearlyStocks ClearlyStocks 8 years ago
VNDA $16.74
๐Ÿ‘๏ธ0
ClearlyStocks ClearlyStocks 8 years ago
$VNDA $16 from $14 now
๐Ÿ‘๏ธ0
nyctraydr nyctraydr 8 years ago
Where Things Stand For Vanda Pharmaceuticals In Fanapt Patent Suit http://marketexclusive.com/things-stand-vanda-pharmaceuticals-inc-nasdaqvnda-fanapt-patent-suit/24951/?icd1
๐Ÿ‘๏ธ0
ClayTrader ClayTrader 8 years ago
* * $VNDA Video Chart 08-25-16 * *

Link to Video - click here to watch the technical chart video
๐Ÿ‘๏ธ0
ClearlyStocks ClearlyStocks 8 years ago
$15.24 weeee
๐Ÿ‘๏ธ0
ClearlyStocks ClearlyStocks 8 years ago
$14.60
๐Ÿ‘๏ธ0
ClearlyStocks ClearlyStocks 8 years ago
$14.22
๐Ÿ‘๏ธ0
ClearlyStocks ClearlyStocks 8 years ago
$14 wow
๐Ÿ‘๏ธ0
GREEN MAKER GREEN MAKER 8 years ago
Approved!!!!!
๐Ÿ‘๏ธ0
jaytea jaytea 8 years ago
VNDA PDUFA Friday:

The FDA has set a user fee goal date under the Prescription Drug User Fee Act of May 27, 2016, which is the target date for the FDA to complete its review of the sNDA.
๐Ÿ‘๏ธ0
jaytea jaytea 8 years ago
VNDA breaks above 200 day MA
๐Ÿ‘๏ธ0
jaytea jaytea 8 years ago
Moving up nicely this morning.
๐Ÿ‘๏ธ0
Ppower Ppower 9 years ago
Nice been following this stock for awhile now and made some good money here.

Also, follow Titan Pharmaceuticals TTNP
๐Ÿ‘๏ธ0
UserAlias1 UserAlias1 9 years ago
Vanda-Pharmaceuticals Reports Fourth-Quarter 2014 and Full-Year 2014 Financial-Results

Last update: 19/02/2015 7:00:18 am

Vanda Pharmaceuticals Reports Fourth Quarter 2014 and Full Year 2014 Financial Results

- HETLIOZ(R) net product sales in the U.S. grew to $6.0 million in the fourth quarter of 2014, a 15% increase as compared to the third quarter of 2014.

- Vanda expects HETLIOZ(R) net product sales for 2015 to grow to between $40 and $45 million.

- Combined 2015 net product sales from both HETLIOZ(R) and Fanapt(R) are expected to be between $95 million and $110 million.

PR Newswire

WASHINGTON, Feb. 19, 2015

WASHINGTON, Feb. 19, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the fourth quarter and full year ended December 31, 2014.

"2014 was a transformational year for Vanda with the HETLIOZ launch in the U.S. for the treatment of Non-24-Hour Sleep-Wake Disorder. We are impressed with the continued growth of HETLIOZ and are fortunate to be able to offer this important treatment option for patients" said Mihael H. Polymeropoulos M.D., Vanda's President and CEO. "The return of the U.S. and Canadian commercial rights to Fanapt brings an immediately accretive product to Vanda further strengthening our U.S. commercial portfolio."

Key Highlights:

HETLIOZ(R) (tasimelteon)
-- HETLIOZ(R) net product sales in the U.S. grew to $6.0 million in the
fourth quarter of 2014, a 15% increase, compared to $5.2 million in the
third quarter of 2014. HETLIOZ(R) net product sales were $12.8 million
for the full year 2014.

-- Since the U.S. commercial launch of HETLIOZ(R) in April 2014, over 760
new patient prescriptions have been written including over 220 in the
fourth quarter of 2014. As of December 31, 2014, over 470 patients had
initiated HETLIOZ(R) treatment and over 330 patients were on active
treatment reflecting a cumulative persistence rate of approximately 70%.

-- The HETLIOZ(R) Marketing Authorization Application in the European Union
(EU) is under review with a regulatory decision expected in the third
quarter of 2015.

-- Tasimelteon life cycle management activities are ongoing and include a
Smith-Magenis Syndrome observational study with results expected in the
first half of 2015 and preparations for a clinical development program
for pediatric Non-24.

-- HETLIOZ(R) exclusivity in the U.S. is protected by orphan exclusivity and
two patents listed in the FDA Orange Book (Orphan exclusivity expiry in
2021; Patent No. 5,856,529 expiry expected in 2022 and Patent No.
8,785,492 expiry in 2033).

Fanapt(R) (iloperidone)
-- Fanapt(R) royalty revenue was $1.6 million for the fourth quarter of
2014, compared to $1.7 million in the third quarter of 2014. Fanapt(R)
royalty revenue was $6.5 million for the full year 2014, compared to $7.1
million for 2013.

-- For the full year 2014, Fanapt(R) U.S. net product sales were $65.0
million, as reported by Novartis AG (Novartis). Fanapt(R) U.S.
prescriptions for the fourth quarter of 2014 were approximately 40,500,
as reported by IMS.

-- On December 31, 2014, the Fanapt(R) U.S. and Canadian rights were
returned to Vanda as part of the settlement of arbitration with Novartis.

-- Fanapt(R) exclusivity in the U.S. is protected by two patents listed in
the FDA Orange Book (Patent No. RE39198 expiry in 2016 and Patent No.
8,586,610 expiry in 2027).

VLY-686 (tradipitant)
-- Results of the Phase II study (2101) of tradipitant, an NK1 receptor
antagonist, in patients with chronic pruritus are expected in the first
quarter of 2015.

Financial Results for the Fourth Quarter and Full Year 2014

Vanda total revenues for the fourth quarter of 2014 were $15.4 million, compared to $8.8 million for the fourth quarter of 2013. Vanda total revenues for the full year 2014 were $50.2 million, compared to $33.9 million for 2013.

Selling, general and administrative expenses were $17.3 million in the fourth quarter of 2014, compared to $9.9 million in the fourth quarter of 2013. Selling, general and administrative expenses were $84.6 million in the full year 2014, compared to $25.1 million in 2013. The increases in selling, general and administrative expenses in fourth quarter and full year 2014 were the result of the U.S. commercial launch support for HETLIOZ(R) .

Research and development expenses were $4.8 million in the fourth quarter of 2014, compared to $6.3 million in the fourth quarter of 2013. Research and development expenses were $19.2 million in the full year 2014, compared to $28.5 million in 2013.

Vanda recorded a $77.6 million gain related to the Novartis arbitration settlement in the fourth quarter of 2014.

Vanda net income was $69.7 million for the fourth quarter of 2014, compared to a net loss of $7.7 million for the fourth quarter of 2013. Diluted net income per share for the fourth quarter of 2014 was $1.77, compared to a net loss per share of $0.23 for the fourth quarter of 2013. Vanda net income was $20.2 million for the full year 2014, compared to a net loss of $21.1 million for 2013. Diluted net income per share for the full year 2014 was $0.55, compared to a net loss per share of $0.69 for 2013.

In October 2014, Vanda completed a public common stock offering that resulted in $62.3 million in net proceeds. In December 2014, Vanda sold $25.0 million of common stock to Novartis as part of the arbitration settlement. Cash, cash equivalents and marketable securities were $129.8 million as of December 31, 2014.

Non-GAAP Financial Results

Vanda Non-GAAP Total revenues for the fourth quarter of 2014 were $7.6 million, compared to $2.0 million for the fourth quarter of 2013. Vanda Non-GAAP Total revenues for the full year 2014 were $19.4 million, compared to $7.1 million for 2013.

Vanda Non-GAAP Net loss was $13.5 million for the fourth quarter of 2014, compared to a net loss of $12.7 million for the fourth quarter of 2013. Non-GAAP Diluted net loss per share for the fourth quarter of 2014 was $0.36, compared to a net loss per share of $0.38 for the fourth quarter of 2013. Vanda Non-GAAP net loss was $80.0 million for the full year 2014, compared to a net loss of $40.9 million for 2013. Non-GAAP Diluted net loss per share for the full year 2014 was $2.30, compared to a net loss per share of $1.35 for 2013.

Vanda provides Non-GAAP financial information, which it believe can enhance an overall understanding of its financial performance when considered together with GAAP figures. Refer to the sections of this press entitled "Non-GAAP Financial Information" and "Reconciliation of GAAP to Non-GAAP Financial Information.

2015 Financial Guidance

Vanda expects to achieve the following financial objectives in 2015:
-- Combined net product sales from both HETLIOZ(R) and Fanapt(R) of between
$95 million and $110 million.

-- HETLIOZ(R) net product sales of between $40 million to $45 million and
Fanapt(R) net product sales of between $55 million to $65 million.

-- Non-GAAP Operating expenses, excluding cost of sales, of between $105
million and $120 million.

In addition, for reporting periods beginning in 2015, Vanda will no longer record Fanapt(R) licensing agreement revenues and will no longer report the number of HETLIOZ(R) prescriptions written, dispensed or patients on therapy.

Full HETLIOZ(R) Prescribing Information can be found at: www.hetlioz.com.

Full Fanapt(R) Prescribing Information, including Boxed Warnings and Important Safety Information can be found at: www.fanapt.com.

Conference Call

Vanda has scheduled a conference call for today, Thursday, February 19, 2015, at 10:00 AM ET. During the call, Vanda's management will discuss the fourth quarter and full year 2014 financial results and other corporate activities. Investors can call 1-800-708-4540 (domestic) or 1-847-619-6397 (international) and use passcode 38933858. A replay of the call will be available beginning Thursday, February 19, 2015 at 12:30 PM ET and will be accessible until Thursday, February 26, 2015, at 11:59 PM ET. The replay call-in number is 1-888-843-7419 for domestic callers and 1-630-652-3042 for international callers. The passcode number is 38933858.

The conference call will be broadcast simultaneously on Vanda's website, www.vandapharma.com. Investors should click on the Investor Relations tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations. The call will also be archived on Vanda's website for a period of 30 days.

Non-GAAP Financial Information

Vanda believes that the Non-GAAP financial information provided in this release can assist investors in understanding and assessing the ongoing economics of the Company's business and reflect how it manages the business internally and sets operational goals. Vanda's "Non-GAAP revenues" excludes the Fanapt(R) licensing agreement revenue. The Company's "Non-GAAP G&A expenses" and "Non-GAAP R&D expenses" exclude stock based compensation. "Non-GAAP net income (loss)" and "Non-GAAP Diluted net income (loss) per share" excludes the Fanapt(R) licensing agreement revenue, stock based compensation, intangible asset amortization and gain on arbitration settlement.

Vanda believes that excluding the impact of these items better reflects the recurring economic characteristics of its business and the Company's use of financial resources and the Company's long-term performance.

This press release includes Non-GAAP Operating expenses, a forward-looking Non-GAAP financial measures under the heading "2015 Financial Guidance". This Non-GAAP financial measures was determined by excluding cost of sales, stock based compensation and intangibile asset amortization. We are unable to reconcile this Non-GAAP guidance to GAAP because it is difficult to predict the future impact of these adjustment.

(MORE TO FOLLOW) Dow Jones Newswires

February 19, 2015 07:00 ET (12:00 GMT)
๐Ÿ‘๏ธ0
lecorb lecorb 9 years ago
Everything comes when you least expect!!!Patience!
๐Ÿ‘๏ธ0
Rentier Rentier 9 years ago
Surprising not much interest in this stock it trades all over the place in the last year.

๐Ÿ‘๏ธ0
lecorb lecorb 10 years ago
Not many investors. VNDA, have a very high margin requirement(70%)

๐Ÿ‘๏ธ0
Zbyte Zbyte 10 years ago
Why doesnt anyone post info on the Vanda board? is it that good or that bad?
๐Ÿ‘๏ธ0
lecorb lecorb 10 years ago
Now I understand the new analyst target $ 6


These are the funds that bought in March 2014

FMR 4.52M $73.37M March 31, 2014
Baker Bros. Advisors 4.45M $72.24M March 31, 2014
Palo Alto Investors 3.22M $52.25M March 31, 2014
Kingdon Capital Management 1.91M $31.08M March 31, 2014
T. Rowe Price Associates 1.75M $28.47M March 31, 2014
STATE STREET CORPORATION 1.55M $25.26M March 31, 2014
GOLDMAN SACHS 1.53M $24.91M March 31, 2014
Inves 1.48M $24.12M March 31, 2014
Paulson & Co 1.39M $22.63M March 31, 2014
SUSQUEHANNA INTERNATIONAL 1.35M $21.92M March 31, 2014
BlackRock Fund Advisors 1.34M $21.71M March 31, 2014
Consonance Capital 1.23M $19.94M March 31, 2014
BVF 1.14M $4.45M March 31, 2013
BlackRock Institutional Trust Company, N.A. 1.08M $17.55M March 31, 2014
Vanguard 1.00M $16.30M March 31, 2014
WALL STREET ASSOCIATES 705100 $11.46M March 31, 2014
BOGLE INVESTMENT MANAGEMENT L P /DE/ 606489 $9.86M March 31, 2014

A total of 22.41 million shares more ( DILUTION)

Average Purchase $ 331,910,000

Average total purchase: $14.81

Now you understand, why they want that you buy?

Besides dilution want to steal. Less

Now I understand analysts TDA
ResearchTeamTM Sell
TheStreet:Sell
S&P Capital IQ:No rating
Ford Equity Research: Strong Sell
MarketEdge:No rating
Jaywalk Consensus:Sell

Now one understands these ratings!

๐Ÿ‘๏ธ0
lecorb lecorb 10 years ago
AMERICAN BULLS: MONDEY, CONFIRMATION: SELL!!



Signal Update

Our systemโ€™s recommendation today is to SELL. The BEARISH ONE BLACK CROW pattern finally received a confirmation because the prices crossed the confirmation level which was at 14,5800, and our valid average selling price stands now at 14,5000. The previous BUY recommendation was issued on 22/05/2014, 22 days ago, when the stock price was 9,9600. Since then VNDA has risen by +45,58%.

Market Outlook

We may be at a market top or at the start of a correction. The market ran out of steam and the traders are now more in agreement about the bearishness. The evidence is strong enough to prompt the closing of long positions. Todayโ€™s candlestick has a black body and its close is below the confirmation level. The bearish pattern that was previously identified is finally confirmed and a SELL signal is generated. You still have time to follow the signal and then you may start checking other securities for a bullish bet. Less

๐Ÿ‘๏ธ0
lecorb lecorb 10 years ago
ZACKS:Ariad Pharmaceuticals had the Lowest Relative Performance in the Biotechnology Industry (ARIA, MNKD, BCRX, INSM, VNDA)

Jun 13, 2014 (Fast Lane via COMTEX) -- Below are five companies in the Biotechnology industry that underperformed yesterday on a relative basis. This analysis was compiled based on yesterday's trading activity as we search for stocks that have could possible underperform its peers going forward.

Ariad Pharmaceuticals (NASDAQ:ARIA) ranks first with a loss of 8.69%; MannKind (NASDAQ:MNKD) ranks second with a loss of 5.51%; and BioCryst Pharmaceuticals (NASDAQ:BCRX) ranks third with a loss of 3.07%.

Insmed (NASDAQ:INSM) follows with a loss of 2.79% and Vanda Pharmaceuticals (NASDAQ:VNDA) rounds out the bottom five with a loss of 2.54%.ARIAD Pharmaceuticals, Inc. discovers and develops breakthrough medicines that regulate cell signaling with small molecules. The Company is primarily focused on product candidates for targeted indications. ARIAD is developing products to treat solid tumors, to block the spread of cancer, to treat certain forms of leukemia, and to treat cancer that has spread to bone and primary bone cancers. Less
๐Ÿ‘๏ธ0
lecorb lecorb 10 years ago
F.TIME:Markit short selling activity is High! 06/13/14

News of China and USA, Irak, are not encouraging.
I think we will have a black friday
๐Ÿ‘๏ธ0
lecorb lecorb 10 years ago
Empire Asset Management initiates coverage at $6.00 at sell.


The chart is about to collapse + new coverage $6.00

Be carefull with the short sellers
๐Ÿ‘๏ธ0
Talc Moan Talc Moan 10 years ago
Nice 8k for VNDA!

http://ih.advfn.com/p.php?pid=nmona&article=62514203&symbol=VNDA
๐Ÿ‘๏ธ0
KingDMC KingDMC 10 years ago
Whooooo! Now that's how winners play! Well done!
๐Ÿ‘๏ธ0
Nolerman Nolerman 10 years ago
Sold half call position for 80%....so far total on Strangle trade 115%
๐Ÿ‘๏ธ0
Nolerman Nolerman 10 years ago
VNDA is rated BUY, based on 3 Wall Street analysts' reports. Analysts have an average $21.33 Target Price on VNDA, implying 78.8% Upside to its current price of $11.93.

Earnings 2/13 before bell
๐Ÿ‘๏ธ0
Rentier Rentier 10 years ago
Time to start coming back down, approval already baked into the stock price. This has been good company to me in the past. :)

Not sure what news could come out to help stock higher, the drug they just had approved as a very small patient population it will service.
๐Ÿ‘๏ธ0
KingDMC KingDMC 10 years ago
$10.85 was a gift...
๐Ÿ‘๏ธ0
Nolerman Nolerman 10 years ago
I'm holding a small portion of calls through March.
๐Ÿ‘๏ธ0
KingDMC KingDMC 10 years ago
They will push this down as far as they can. I'm sure many bought above $13 and $14 and are now stuck holding the bag. But this would be a good entry point for when more news does pop like you say.
๐Ÿ‘๏ธ0
Nolerman Nolerman 10 years ago
Wait and see....patience. The CC could mention something that would be good for another 10% pop. Tea leaves about pricing of product or any number of factors could drive this one either direction pretty quickly.
Be ready and nimble....the pop (if at all) would likely be short lived. Seems conformation bias plagues this one.
๐Ÿ‘๏ธ0
KingDMC KingDMC 10 years ago
News already priced in it seems. I've seen this a few times where a stock drops on news as opposed to sky rocketing. I think it will pull back a bit more as people jump ship.
๐Ÿ‘๏ธ0
poolguy1 poolguy1 10 years ago
we had really good news now-now what, the shares are not responding according to the media buzz? how can that be?
๐Ÿ‘๏ธ0
Nolerman Nolerman 10 years ago
Which is the exact reason I chose March options on this one. Let it shake out
๐Ÿ‘๏ธ0
KingDMC KingDMC 10 years ago
Everyone looking to jump ship it seems....
๐Ÿ‘๏ธ0
Nolerman Nolerman 10 years ago
Absolute battle right here at 14
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock